Kleinostheim, Germany, 18th February 2010 – curasan AG, listed in the General Standard of the Deutsche Börse AG (ISIN: DE 000 549 453 8), is commencing the sale, through a subsidiary, of its synthetic bone regeneration material Cerasorb® M Ortho in the United States.
The newly founded curasan Inc., with its headquarters in Massachusetts, is responsible for commercial and logistical management as well as marketing activities. This occurs in coordination with the head office in Germany. The processing of orders and shipment is undertaken by specialist service providers, in order to avoid the need to staff such activities locally. Local sales will occur through an external dealer network that specialises in targeting orthopaedists, trauma surgeons and spine surgeons.
For some regions, sales contracts already exist; in the remaining states, the sales network will be expanded during the course of the year. Independent representatives and distributors experienced with these targeted customer groups and interested in pursuing this exciting opportunity are encouraged to contact the US office at office@curasan.com.
“Because we have already previously established and successfully disposed of a subsidiary in the US for the dental market, we are now benefiting from that experience”, stated Hans Dieter Rössler, CEO of curasan AG.
“At almost US$ 1 billion, the market potential for bone regeneration materials in orthopaedics, trauma surgery and traumatology in the US is extremely attractive. Human bones from tissue banks form the largest proportion of this material; however, the share of synthetic bone replacement materials has clearly risen more sharply than the overall market in the last few years and is predicted to take over the market leadership within the next three years. The aim of our US activities is to participate at a manageable cost in this market development with the synthetic Cerasorb® M Ortho.”
From 9th - 13th March 2010, curasan Inc. will be occupying a trade fair stand during the American Academy of Orthopaedic Surgeons (AAOS) conference in New Orleans. This is the world’s largest event for orthopaedists and related healthcare experts.
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.
